

## Plain English Summary

# Bevacizumab biosimilar for treating different types of cancer

### What does the guidance say?

Bevacizumab biosimilar (Mvasi) is recommended for listing on the Standard Drug List (SDL) for government subsidy to treat certain types of cancers.

Bevacizumab reference biologic (Avastin) is not recommended for subsidy to treat cancer. Other brands of bevacizumab biosimilar are also not recommended for subsidy.

### What is Mvasi?

Mvasi is a biosimilar of a biologic drug called bevacizumab (Avastin). It belongs to a group of medicines called vascular endothelial growth factor (VEGF) inhibitors that stop cells from growing blood vessels and slow or shrink tumour growth.

Mvasi is given as a drip into a vein (intravenously), usually as part of a combination of cancer medicines. Your doctor will tell you how much you need to take and how long you need to take it for.

### What is a biosimilar?

Biologics are medicines that contain active ingredients extracted from living organisms. Biosimilars are also biologics. They are highly similar, but not identical to their reference biologics (i.e., the first biologic developed). Biosimilars have similar effectiveness, safety and quality records compared to their reference biologics and can be used to treat the same diseases.

### Why was Mvasi recommended for subsidy?

ACE evaluates how well a treatment works in relation to how much it costs compared to other treatments. Mvasi (bevacizumab biosimilar) was recommended because its benefit in improving survival for certain patients with different types of cancer justifies its cost.

Avastin (bevacizumab reference biologic) was not recommended for subsidy because its benefits do not justify its cost compared with Mvasi. Other brands of bevacizumab biosimilar were not reviewed for subsidy.

## Plain English Summary

# Bevacizumab biosimilar for treating different types of cancer

## Who can have Mvasi?

Mvasi is approved for use for different types of cancers including:

- cervical cancer
- colorectal cancer
- epithelial ovarian, fallopian tube, or primary peritoneal cancer
- non-squamous non-small-cell lung cancer, and
- malignant glioma (WHO Grade III and IV).

All approved uses have been recommended for subsidy. Patients must meet certain clinical criteria to receive treatment. Your doctor can advise if Mvasi is a suitable treatment for you.

## What does listing on SDL mean for me?

Drugs on SDL are subsidised at 50% for all Singaporean citizens who are treated in a public healthcare institution. Patients from lower to middle income households may receive up to 75% subsidy.

**Published: 1 April 2022**

The Agency for Care Effectiveness (ACE) was established by the Ministry of Health (Singapore) to drive better decision-making in healthcare through health technology assessment (HTA), clinical guidance and education. It publishes guidances on diagnosing, treating, and preventing different medical conditions based on the latest research information available worldwide.

This summary is not, and should not be regarded as, a substitute for professional or medical advice. Please seek the advice of a qualified healthcare professional about any medical condition.

*To find out more about ACE visit [www.ace-hta.gov.sg](http://www.ace-hta.gov.sg)*